Barclays raised the firm’s price target on Tandem Diabetes (TNDM) to $55 from $51 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as solid and sees a “healthy” pipeline.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $18 from $16 at Baird
- Tandem Diabetes Care Reports Record Third-Quarter Sales
- Tandem Diabetes Care: Strong Q3 Performance and Positive Outlook Justify Buy Rating
- Tandem Diabetes reports Q3 EPS (31c), consensus (34c)
- Tandem Diabetes affirms FY25 revenue view of $1.0B, consensus $1.0B